Uma Chowdhry

UMA CHOWDHRY, Business Director, Intermediates, DuPont Specialty Chemicals, Wilmington, Del. "By reading THE SCIENTISTregularly, I can track who is doing what in the field I have my roots in. THE SCIENTIST provides me with a quick review of the most significant developments in science and technology." It is not often that a researcher gets the opportunity to become director of a business based on the technology he or she was involved in. But that is what happened to DuPont's Uma Chowdhry. Sh

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

UMA CHOWDHRY, Business Director, Intermediates,
DuPont Specialty Chemicals, Wilmington, Del.

"By reading THE SCIENTISTregularly, I can track who is doing what in the field I have my roots in. THE SCIENTIST provides me with a quick review of the most significant developments in science and technology."

It is not often that a researcher gets the opportunity to become director of a business based on the technology he or she was involved in. But that is what happened to DuPont's Uma Chowdhry.

Shortly after joining DuPont in 1977, Chowdhry led a group to develop catalysts for making tetrahydrofuran from butane in a two-step process. The inventions pioneered by her group were later developed by large, interdisciplinary teams into a new commercial process. Chowdhry is now director of a $400 million business that is capitalizing on her group's original research.

"I feel fortunate to have come full circle to be director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies